1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,648 | 0,676 | 16:45 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Tevogen Bio Inc: Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest | 65 | GlobeNewswire (Europe) | Company intends to collaborate with government initiatives, Long COVID patient organizations, and major healthcare providers to expedite development of TVGN 489In recognition of the high volume of... ► Artikel lesen | |
| 26.09. | Tevogen Bio Holdings verstößt gegen NASDAQ-Mindestkursanforderung | 3 | Investing.com Deutsch | ||
| 26.09. | Tevogen Bio Holdings Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 25.09. | Tevogen Bio Inc: Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell-Based Therapies with 100x PredicTcell Beta Data Expansion | 145 | GlobeNewswire (Europe) | Beta version of PredicTcell expands training dataset to ~1.4 million and total dataset to over 6.7 billion records.Potential future T cell therapies could reliably bind to their target nearly every... ► Artikel lesen | |
| 23.09. | Tevogen Bio Inc: Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID | 1 | GlobeNewswire (USA) | ||
| 19.09. | Tevogen Bio Inc: Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489's Potential Impact for 20 Million Americans | 1 | GlobeNewswire (USA) | ||
| 10.09. | Tevogen Bio Inc: Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston | 1 | GlobeNewswire (USA) | ||
| TEVOGEN BIO Aktie jetzt für 0€ handeln | |||||
| 09.09. | Tevogen Bio Inc: Tevogen Estimates 5-Year Top-Line Revenue of ~$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection | 91 | GlobeNewswire (Europe) | Risk adjusted Net Present Value (rNPV) for TVGN 116 is estimated to exceed ~$325 million in the US alone. WARREN, N.J., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company")... ► Artikel lesen | |
| 08.09. | Tevogen announces $9-11 billion valuation for COVID-19 T cell therapy | 2 | Investing.com | ||
| 08.09. | Tevogen Bio Inc: Tevogen Values TVGN-489 at $9-$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell Allogeneic T Cell Platform | 162 | GlobeNewswire (Europe) | WARREN, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), today shared the risk-adjusted net present value (rNPV) estimate of $9 billion to... ► Artikel lesen | |
| 04.09. | Tevogen shares EBV treatment forecast with $3.5 billion revenue potential | 2 | Investing.com | ||
| 04.09. | Tevogen Bio Inc: Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas | 98 | GlobeNewswire (Europe) | The risk adjusted Net Present Value (rNPV) for TVGN 930 is estimated to exceed ~$250 million in the US alone.Covering five rare disease eligible indications, the accessible market in the US could... ► Artikel lesen | |
| 03.09. | Tevogen highlights need for SARS-CoV-2 treatments for immunocompromised | 2 | Investing.com | ||
| 03.09. | Tevogen Bio Inc: Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2 | 105 | GlobeNewswire (Europe) | WARREN, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), today highlighted the continuing need for SARS-CoV-2 treatments for individuals... ► Artikel lesen | |
| 27.08. | Tevogen Bio Inc: Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure | 120 | GlobeNewswire (Europe) | WARREN, N.J., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), today updated investors of its significant internally developed assets, which under... ► Artikel lesen | |
| 26.08. | Tevogen Bio Inc: Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company's Mission of Health Equity | 1 | GlobeNewswire (USA) | ||
| 25.08. | Tevogen Bio Inc: Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions | 221 | GlobeNewswire (Europe) | WARREN, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), today announced an update on institutional ownership of the Company's outstanding... ► Artikel lesen | |
| 22.08. | Tevogen Bio Inc: Tevogen Recognized in BINJE's BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma | 1 | GlobeNewswire (USA) | ||
| 19.08. | Tevogen Bio Holdings reports Q2 results | 1 | Seeking Alpha | ||
| 19.08. | Tevogen Bio Inc: Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum | 167 | GlobeNewswire (Europe) | Expenses significantly lower with expansion on multiple efforts; Q2 2025 loss from operations reduced to $5.4 million vs $8.6 million in Q2 2024.Tevogen maximizes capital efficiency, maintains access... ► Artikel lesen |
1 2 3 4 5 Weiter >>
103 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 41,450 | +1,97 % | QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast | QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date time: Tuesday, November 4, shortly after 22:05... ► Artikel lesen | |
| AMGEN | 257,60 | +0,86 % | Here's What to Expect From Amgen's Next Earnings Report | ||
| NOVAVAX | 7,674 | +0,34 % | NOVAVAX INC zündet den Turbo - jetzt wird's brisant! | ||
| PALATIN TECHNOLOGIES | - | - | Palatin Technologies, Inc.: Palatin Earns €5.5 Million ($6.5 Million) Milestone Payment in Retinal Disease Collaboration with Boehringer Ingelheim | Collaboration focused on developing potential first-in-class melanocortin receptor targeted treatment for patients with diabetic retinopathy, including diabetic... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 499,20 | +0,81 % | Regeneron Pharma Reports Promising Results For DB-OTO Gene Therapy In Genetic Hearing Loss | WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals Inc. (REGN) announced encouraging new data for its investigational gene therapy, DB-OTO, aimed at treating profound genetic hearing loss caused... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 2,220 | +0,91 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Inducement Grant Under Inducement Plan | PLYMOUTH MEETING, Pa., Oct. 2, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem Corp.: Sirona Biochem Update to Shareholders on Financial Status and Operations | VANCOUVER, British Columbia, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) ("Sirona") wishes to provide shareholders with a critical update on the company's financial... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 2,160 | -0,92 % | COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update | COSCIENS Board of Directors approves a plan to voluntarily delist from Nasdaq, while retaining the Company's listing on the TSX TORONTO, ONTARIO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 45,330 | -0,59 % | BioMarin stock price target lowered to $80 at Cantor Fitzgerald | ||
| NUREXONE BIOLOGIC | 0,602 | +1,01 % | Breaking News: Erblindete Augen erholen sich zu 100%! | ||
| ARROWHEAD PHARMACEUTICALS | 33,600 | +2,41 % | ARROWHEAD PHARMACEUTICALS, INC. - 10-K/A, Annual Report | ||
| XOMA ROYALTY | 31,800 | -1,24 % | XOMA Royalty Corporation Extends Tender Offer to Acquire LAVA Therapeutics N.V. | EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Oct. 02, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ: XOMA) and LAVA Therapeutics N.V. ("LAVA") (Nasdaq:... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 2,240 | 0,00 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series | King of Prussia, Pennsylvania--(Newsfile Corp. - September 23, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its... ► Artikel lesen | |
| T2 BIOSYSTEMS | 0,250 | 0,00 % | NSE/A - T2 Biosystems, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - 10-Q, Quarterly Report |
Das Unternehmen TEVOGEN BIO HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,032 (-4,98 %) liegt der Kurs bei 0,610 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TEVOGEN BIO HOLDINGS INC finden Sie auf Wallstreet Online.